CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares Tevogen Bio Reports Second Quarter 2024 Financial Results

Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares Tevogen Bio Reports Second Quarter 2024 Financial Results

Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq:...

ISW Holdings Announces Elimination of More Than $2.4M (92%) of Outstanding Convertible Debt LAS VEGAS, April 07, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – ISW Holdings, Inc. (OTC: ISWH) (“ISW Holdings” or the “Company”), a global brand management holdings company with commercial...

Flexible AC Transmission Systems Market to hit $2.5 billion by 2025: Global Market Insights, Inc. Sellbyville, Delaware, March 26, 2019 (GLOBE NEWSWIRE) -- The Flexible AC transmission systems market across Africa, Asia Pacific and Middle East has observed a substantial growth in conjunction to...